OncoMatch/Clinical Trials/NCT05069220
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Is NCT05069220 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including 18F-MFBG and 68Ga-Dotatate for neuroendocrine tumor.
Treatment: 18F-MFBG · 68Ga-Dotatate — The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Radioligand therapy
Other
Cancer type
Neuroendocrine Tumor
Neuroblastoma
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05069220 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages